AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04555746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
Study NCT02312310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Flavanol
Description: 12 weeks administration of cocoa flavanol
Study NCT02312310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Flavanol
Description: 12 weeks administration of cocoa flavanol
Study NCT04401124 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01168999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
Study NCT00969267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear-acupuncture A
Description: with needle stimulation
Study NCT00969267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stimulation B
Description: with bread stimulation on ear acupuncture point
Study NCT00969267 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stimulation C
Description: without needle stimulation
Study NCT01823250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Therapy based on Structural Family Therapy
Description: Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
Study NCT01823250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Therapy based on Structural Family Therapy
Description: Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
Study NCT01823250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy
Description: Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
Study NCT01823250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Sessions
Description: Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
Study NCT01823250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Adolescent Therapy Sessions
Description: Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
Study NCT03004417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 6001 Dose1
Description: CHF 6001 plus placebo
Study NCT03004417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 6001 Dose2
Description: CHF 6001 only (high dose)
Study NCT01168999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham spinal manipulation
Description: Sham spinal manipulation intended to mimic the studied spinal manipulation
Study NCT01168999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced sham spinal manipulation
Description: Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people
Study NCT01498926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
Study NCT01498926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
Study NCT04364633 — intervention group
Intervention type: OTHER
Intervention: Voice Handicap Questionnaire (VHI)
Description: Voice Handicap Index (VHI) self-questionnaire
Study NCT03219333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
Study NCT05165121 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MDHearing smart hearing aid
Description: air conduction hearing aid with app support
Study NCT02851576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of ADV specific T cells
Description: Cell engineering
Study NCT01963624 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonography
Description: Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
Study NCT05734092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional orthodontic treatment
Description: As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
Study NCT05734092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser
Description: The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage.
Study NCT00491244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
Study NCT00491244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
Study NCT00318487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral sinus augmentation with immediately loaded dental implants
Description: Bilateral sinus augmentation with immediately loaded dental implants will be used.
Study NCT01126541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
Study NCT02829359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir therapy
Description: Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
Study NCT04578314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relating Therapy
Description: Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
Study NCT04578314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
Study NCT04578314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
Study NCT03654677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated hepatitis A vaccine
Description: A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
Study NCT03654677 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Inj
Description: A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
Study NCT03160703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica
Description: Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study NCT03160703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)
Description: Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study NCT03160703 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80
Description: Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study NCT03160703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous fluoride (SnF2, 0.454%), RDA~120
Description: Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study NCT02809976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Phosphate Cream
Description: twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
Study NCT04229719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-5-methoxytryptamine
Description: 1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
Study NCT02738021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRONG
Description: A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
Study NCT03175042 — intervention group
Intervention type: DEVICE
Intervention: Masimo spot hemoglobin non-invasive monitor
Description: This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
Study NCT01513291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
Study NCT01513291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 2 tablets, orally, once daily
Study NCT01513291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets, orally, once daily
Study NCT03004417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo only
Study NCT00452335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 mcg capsule once daily (QD)
Study NCT03724292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo administered as oral capsule(s) once daily
Study NCT03724292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as oral capsule(s) once daily
Study NCT00452335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 mcg capsule twice daily (BID)
Study NCT00452335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg capsule twice daily (BID)
Study NCT02984995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
Study NCT04077034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formula Bacillus subtilis DE111®
Description: Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
Study NCT03878056 — intervention group
Intervention type: DEVICE
Intervention: Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific
Description: Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
Study NCT04077034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator, once a day for 8 weeks
Study NCT04354831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: * SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion
Study NCT00002949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
Study NCT03728582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS plus Speech-Language Therapy
Description: 1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
Study NCT03728582 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active tDCS plus Speech-Language Therapy
Description: 1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
Study NCT03728582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS plus Speech-Language Therapy
Description: Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
Study NCT03728582 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS plus Speech-Language Therapy
Description: Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
Study NCT03062488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO acetaminophen
Description: multi-modal analgesia with PO acetaminophen
Study NCT02014402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human thrombin
Description: Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
Study NCT01946308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conformational positioning system
Description: The conformational positioning system will be compared to the standard infant crib mattress.
Study NCT03587259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Description: DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
Study NCT03587259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 2D mammography
Description: 2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
Study NCT04384536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural therapy application
Description: Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
Study NCT01034397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
Study NCT00002949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
Study NCT01034397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv every 4 weeks for 24 weeks
Study NCT01034397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-biological DMARDs
Description: stable dose at investigator's prescription
Study NCT00002949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
Study NCT02204709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2N Trout
Description: Diploid/2N trout source
Study NCT02204709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3N Trout
Description: Triploid/3N trout source
Study NCT01034397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-biological DMARDs
Description: stable dose at investigator's prescription
Study NCT00476424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
Study NCT02204709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilapia
Description: Tilapia/control fish source
Study NCT02879552 — intervention group
Intervention type: PROCEDURE
Intervention: Traditional upper blepharoplasty
Description: The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.